← Back to Search

Other

GLY-200 for Type 2 Diabetes

Phase 2
Waitlist Available
Research Sponsored by Glyscend, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 7, and day 14
Awards & highlights

Study Summary

This trial is testing a new diabetes drug to see if it is safe and works better than the current best treatment.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 7, and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 7, and day 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events [safety and tolerability of GLY-200]
Secondary outcome measures
Change from baseline in 3-hours postprandial plasma glucose profile
Change from baseline in 3-hours postprandial plasma insulin profile
Change from baseline in fasting plasma glucose
+1 more

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: 2.0 g GLY-200Experimental Treatment1 Intervention
Group II: 1.0 g GLY-200Experimental Treatment1 Intervention
Group III: 0.5 g GLY-200Experimental Treatment1 Intervention
Group IV: Placebo for 0.5 g GLY-200 armPlacebo Group1 Intervention
Group V: Placebo for 1.0 g GLY-200 armPlacebo Group1 Intervention
Group VI: Placebo for 2.0 GLY-200 armPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GLY-200
2022
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Glyscend, Inc.Lead Sponsor
1 Previous Clinical Trials
70 Total Patients Enrolled
Mark Fineman, PhDStudy ChairGlyscend, Inc.
1 Previous Clinical Trials
70 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is GLY-200 officially certified by the FDA?

"Using a scale of 1 to 3, our team at Power has appraised the safety profile of GLY-200 as '2'. This is because this Phase 2 trial features some evidence regarding its security yet lacks data on efficacy."

Answered by AI

What criteria must be met to participate in this clinical experiment?

"This trial is actively searching for 48 individuals aged between 30 and 70 who have been diagnosed with type 2 diabetes mellitus. Of note, applicants must possess a Body Mass Index that falls between 18 to 40 at screening as well as an HbA1c level ranging from 6 to 8.5%."

Answered by AI

Does the enrollment criteria for this experiment include individuals above 80 years of age?

"This study requires prospective participants to be between 30 and 70 years old. Those under the age of 18 have access to 52 clinical trials, while those above 65 can choose from 736 available options."

Answered by AI

Are there opportunities for people to participate in this experiment?

"Affirmative, the information published on clinicaltrials.gov reveals that this trial is currently in search of participants. Initially posted 8th March 2022 and last amended 28th October 2022, 48 patients are required to be recruited from a single location."

Answered by AI

What is the cap on the number of participants involved in this clinical trial?

"Affirmative. The clinicaltrials.gov website asserts that this medical research, which was originally announced on August 3rd 2022, is currently looking for participants. A total of 48 individuals need to be enrolled from 1 separate healthcare facility."

Answered by AI
~20 spots leftby Mar 2025